Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06311045 · ClinicalTrials.gov registry record · NA
Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)
A NA study of Obstructive Sleep Apnea, sponsored by NYU Langone Health.
- Active
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT06311045: Active NA study of Obstructive Sleep Apnea, sponsored by NYU Langone Health.
NCT06311045 is a NA study of Obstructive Sleep Apnea that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 14 participants, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06311045, a NA study of Obstructive Sleep Apnea, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized controlled trial (RCT) of 4 weeks of study supplement N-acetylcysteine (NAC) versus placebo in persons with significant obstructive sleep apnea (OSA) who are receiving positive airway pressure therapy (PAP), the standard of care therapy. The purpose of the study is to determine if NAC is associated with sex-specific changes in overnight oxidative stress, inflammation, as well as endothelial dysfunction in persons with OSA.
Primary Outcome
GSH measured using participant blood samples.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT N-acetylcysteine (NAC)
- PROCEDURE Positive Airway Pressure (PAP) Therapy
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2024-05-07 |
| Est. Completion | 2026-04 |
| Phase | NA |
What the registry record for NCT06311045 still lists
NCT06311045 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06311045 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06311045 about?
NCT06311045 is a clinical study titled "Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)". This is a randomized controlled trial (RCT) of 4 weeks of study supplement N-acetylcysteine (NAC) versus placebo in persons with significant obstructive sleep apnea (OSA) who are receiving positive airway pressure therapy (PAP), the standard of care therapy. The purpose of the study is to determine ...
What is the current status of trial NCT06311045?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 14 participants. The study started on 2024-05-07. Estimated completion is 2026-04.
What conditions does trial NCT06311045 study?
This clinical trial studies the following conditions: Obstructive Sleep Apnea.
What interventions are being tested in trial NCT06311045?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), N-acetylcysteine (NAC) (DIETARY_SUPPLEMENT), Positive Airway Pressure (PAP) Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT06311045?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06311045 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Sleep Apnea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06311045's enrollment target sits among peer trials
14 149th of 155 higher than 7 of 155 other Obstructive Sleep Apnea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obstructive Sleep Apnea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
RECRUITING · NA
-
Cognition After OSA Treatment Among Native American People (CATNAP)
RECRUITING · NA
-
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
RECRUITING · NA
-
Mandibular Advancement Device and Changes in Nocturia
RECRUITING · NA
-
Severe Label Expansion for EVO Products Trial
RECRUITING · NA
-
App-Based Optimization of Long-Term CPAP Adherence and Quality of Life
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy